University of Southampton
Development of a novel plant expressed conjugate vaccine for HER2-positive breast cancer
Abstract
dc:description.abstractOverexpression HER2/neu correlates with poor prognosis in many cancers, including breast cancer. HER2-specific monoclonal antibodies including Herceptin® have had significant impact on breast cancer survival rates. However, there are a number of limitations with their use, including tumour recurrence, the requirement for multiple doses and high-cost production. Vaccination, however, can provide long-term tumour specific antibodies and cellular-mediated immune responses. Here the aim was to develop a potent vaccine to target HER2.<br/> <br/>Self-tumour antigen HER2 is poorly immunogenic due to tolerance. Previous studies using DNA vaccines demonstrated that conjugation of tumour antigens to Fragment C of tetanus toxin (FrC) broke tolerance. Here to target HER2 a novel HER2 portion ED44 was generated and conjugated to FrC. The HER2-targeting vaccine subunits were expressed using an efficient plant-based manufacturing process 'magnifection' and were available through collaboration (ICON Genetics, Germany). <br/><br/>Both rat and human versions were generated to study the mechanisms or for clinical application respectively. They were tested in several complementary breast cancer models including non-tolerant (TUBO, D2F2/E2) and tolerant (Balb/neuT) settings. In non-tolerant settings unconjugated ED44 was effective at inducing of protective antibody. In the tolerant model, only ED44-FrC conjugate was effective in inducing high levels of antibody and suppressing already developed tumours. Only ED44-FrC conjugate vaccine induced antibody of high affinity of a wide range of isotypes. FrC-specific T cell help induced by the conjugate vaccine was critical for effective anti-HER2 antibody. <br/><br/>The human ED44-FrC induced sera were able to inhibit HER2-mediated downstream signalling and induced growth inhibition of two HER2positive cell lines. Hence, the novel vaccine is a promising candidate for HER2 positive cancer treatment.<br/><br/>In the last chapter a novel vaccine design that included plant virus particle (PVP) was used to induce anti-HER2 cytotoxic T cells. This sets the foundation for development of this platform in the future.
Degree
thesis:*- Name dc:type.qualificationname
- Ph.D.
- Level dc:type.qualificationlevel
- doctoral
- Grantor dc:publisher.institution
- University of Southampton
- Year dc:date.issued
- 2016
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- Chotprakaikiat, Warayut
- Advisors dc:contributor.advisor
-
- Savelyeva, Natalia
- Ottensmeier, Christian
- Stevenson, Freda
- ORCID person:identifier.orcid
Rights
- Language dc:language
- English, eng